Table-2:
Patient characteristics of the cohorts utilized to correlate CMS and overall survival
| N = 345 | ||
|---|---|---|
| Mean Age at Initial Diagnosis (SD) | 50.9 (11.5) | |
| Mean Age at Stage IV Diagnosis (SD) | 51.5 (11.5) | |
| Sex | ||
| Male | 187 (54.2) | |
| Female | 158 (45.8) | |
| Race/Ethnicity | ||
| Non-Hispanic (NH) White | 258 (74.8) | |
| NH African American | 32 (9.3) | |
| Hispanic | 27 (7.8) | |
| NH Asian | 22 (6.4) | |
| Other/Unknown | 6 (1.7) | |
| Stage at Initial Diagnosis | ||
| I | 5 (1.4) | |
| II | 24 (7.0) | |
| III | 110 (31.9) | |
| IV | 204 (59.1) | |
| NA | 2 (0.6) | |
| KRAS mutation status | ||
| wild type | 107 (31.0) | |
| canonical mutation | 147 (42.6) | |
| NA | 91 (26.4) | |
| NRAS mutation status | ||
| wild type | 236 (68.4) | |
| canonical mutation | 17 (4.9) | |
| non-canonical mutation | 1 (0.3) | |
| NA | 91 (26.4) | |
| BRAF mutation status | ||
| wild type | 229 (66.4) | |
| v600 | 20 (5.8) | |
| other mutation | 5 (1.4) | |
| NA | 91 (26.4) | |
| MSI status | ||
| MSS | 177 (51.3) | |
| NA | 168 (48.7) | |
| Consensus Molecular Subtype | ||
| 1, Immune | 12 (3.5) | |
| 2, Canonical | 117 (33.9) | |
| 3, Metabolic | 21 (6.1) | |
| 4, Mesenchymal | 161 (46.7) | |
| Mixed | 34 (9.9) | |